Clinical trial
Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent…
NCT00171938 · Novartis, Industry · Terminated
Key facts
| NCT number | NCT00171938 |
|---|---|
| Title | Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) |
| Official title | Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) |
| Lead sponsor | Novartis, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Enrollment | 30 |
| Start date | Apr 1, 2004 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Feb 24, 2017 |
| Countries | Brazil |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: